Stratifying cardiovascular benefits from GLP-1RA: a multisource analysis of patient-level CVOT and real-world data using AI-driven methods
This study supports the integration of individual data from CVOT with those from EHR to confirm the transposition of results from CVOT to real-world populations, and enables the identification and validation of subgroups with greater cardiovascular benefits from cardioprotective treatment such as GLP-1RA treatment. This precision medicine approach represents a new framework for deploying cardiovascular prevention strategies in T2D.
Authors
- Agostino Consoli (ORCID: https://orcid.org/0000-0002-1885-451X)
- Emily Donatiello
- Enrico Longato (ORCID: https://orcid.org/0000-0001-5940-645X)
- Gian Paolo Fadini (ORCID: https://orcid.org/0000-0002-6510-2097)
- Angelo Avogaro (ORCID: https://orcid.org/0000-0002-1177-0516)
- Veronica Sciannameo (ORCID: https://orcid.org/0000-0002-0499-0131)
- Paola Berchialla (ORCID: https://orcid.org/0000-0001-5835-5638)
- Mario Luca Morieri (ORCID: https://orcid.org/0000-0001-6864-0547)
Institutions
- University of Padua (IT)
- University of Chieti-Pescara (IT)
- Veneto Institute of Molecular Medicine (IT)
- Novo Nordisk (Italy) (IT)
- Department of Public Health (US)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1186/s12933-025-02952-w
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00